AstraZeneca
6 stories in The Vital Record · Company
-
· Research
AstraZeneca's Oral GLP-1 Pill Trims 11.8% Body Weight in Phase 2 — Phase 3 Now Enrolling -
· Research
In a diabetes trial, a heart-failure drug's benefit looked largest in 121 patients carrying a cardiomyopathy gene variant — an exploratory signal -
· Clinical Trials
Neoadjuvant Osimertinib Meets Pathology Endpoint (~25% vs 2%) in a Phase III Resectable EGFR-Mutant Lung Cancer Trial — Survival Signal Not Yet Significant -
· FDA & Regulatory
EU regulators back AstraZeneca's camizestrant for ESR1-mutated breast cancer, guided by a ctDNA early-switch strategy -
· Clinical Trials
AstraZeneca opens VECTRA-01, a Phase 3 test of alpha-emitter AZD2265 in prostate cancer after beta-emitter therapy -
· FDA & Regulatory
FDA approves baxdrostat, the first aldosterone synthase inhibitor for hard-to-control hypertension